Direxion Daily CSI China Internet Bull 2X Shares vs Gilead Sciences, Inc. — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $24.55, while Gilead Sciences, Inc. trades at $135.99 (market cap $164.99B). The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while Direxion Daily CSI China Internet Bull 2X Shares pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| CWEB | GILD | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $60.13 | $155.80 |
52-Week Low | $17.70 | $110.56 |
Market Cap | — | $164.99B |
Enterprise Value | — | $188.06B |
Dividend Yield | — | 2.47% |
Signals from Pluang's Aura AI — not financial advice
CWEB trades at $25.53, up 1.67% today, with a bullish technical signal from moving averages. The stock shows strong momentum indicators but an overbought short-term RSI. A dividend of $0.09 is scheduled for June 2026, reflecting potential income return. Recent news highlights renewed interest in China growth stocks, which may benefit CWEB's positioning.
The outlook for CWEB is cautiously optimistic, driven by positive technical trends and sector sentiment. Key risks include reliance on China market dynamics and potential volatility. Investment opportunity lies in growth stock resurgence, but investors must weigh macroeconomic and regulatory uncertainties in the region.
Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.
The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.
Trailing returns across standard periods
Latest headlines on both assets
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →